abrdn plc Makes New Investment in Oculis Holding AG (NASDAQ:OCS)

abrdn plc acquired a new stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,452,741 shares of the company's stock, valued at approximately $15,980,000. abrdn plc owned 3.99% of Oculis at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC acquired a new stake in Oculis during the 2nd quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA lifted its stake in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock valued at $1,053,000 after acquiring an additional 30,750 shares during the period. Finally, Wolverine Asset Management LLC acquired a new stake in Oculis during the 3rd quarter valued at approximately $77,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OCS has been the subject of several analyst reports. HC Wainwright decreased their target price on shares of Oculis from $29.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday. Chardan Capital reiterated a "buy" rating and issued a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. Wedbush reiterated an "outperform" rating and issued a $29.00 target price on shares of Oculis in a research note on Wednesday, March 6th. Finally, Robert W. Baird decreased their target price on shares of Oculis from $64.00 to $35.00 and set an "outperform" rating for the company in a research note on Tuesday, March 19th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $29.14.

Oculis Stock Down 0.3 %

NASDAQ OCS traded down $0.03 on Thursday, hitting $11.95. The company had a trading volume of 25,315 shares, compared to its average volume of 46,128. Oculis Holding AG has a 12-month low of $9.05 and a 12-month high of $14.50. The company's fifty day moving average price is $11.88 and its 200-day moving average price is $11.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.29 and a quick ratio of 5.29.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.28 million. As a group, analysts anticipate that Oculis Holding AG will post -1.75 EPS for the current fiscal year.

Oculis Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.